On April 7, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) again raised the limit to a record high closing price of 38.16 yuan / share (former reinstatement), with a cumulative increase of 94.69% this year. Among the stocks on the list on the same day, the net purchase amount of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) funds topped the list, reaching 268 million yuan.
On the same day, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) issued a stock trading announcement, saying that the closing price of the company’s shares rose by 21.9% on April 6 and April 7 for two consecutive trading days. It is confirmed that the company has no matters that should be disclosed but not disclosed.
institutions’ three-day net purchase
Institutions and hot money trading are active. As of the closing on April 7, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) full day turnover reached 6.686 billion yuan. According to the company’s Dragon and tiger list data on the same day, Shenzhen Stock connect bought 241 million yuan of special seats and sold 185 million yuan, ranking first in buying and selling seats; Institutional seats were purchased three times and sold five times, with one net purchase of 109 million yuan and one net sale of 547697 million yuan.
The data of the three-day list released on the same day showed that the funds of the dragon and tiger list bought a net of 846766 million yuan. Among them, the special seats of Shenzhen Stock connect bought 409 million yuan and sold 286 million yuan, ranking first in buying and selling seats Guotai Junan Securities Co.Ltd(601211) Shanghai branch and China stock market news, the first securities business department of Tuanjie Road, Lhasa, ranked among the top five in terms of purchase amount, with net purchases of 221 million yuan and 209931 million yuan respectively.
On April 7, the institution participated in the trading of 19 dragon and tiger list stocks, of which 9 stocks were net bought Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) net purchases topped the list, with a net purchase of 111 million yuan by institutions.
anti epidemic products promote performance growth
Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) 317 announcement said that Lianhua Qingwen capsule and its wholly-owned subsidiary Lianhua Qingwen granule were classified as “New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth)” as a recommended light and general recommendation for Chinese medicine treatment during medical observation and clinical treatment (confirmed cases).
According to the announcement, in April 12, 2020, the State Food and Drug Administration approved Lianhua Qingwen capsules (granules) on the basis of the original approved indications to increase the new indications of “New Coronavirus pneumonia with light and ordinary type”. Since the outbreak of COVID-19, Lianhua Qingwen capsule (granule) has been continuously recommended by New Coronavirus pneumonia diagnosis and treatment plan (Trial fourth / five / six / seven / 8 edition) as a recommended period for Chinese medicine treatment.
On the afternoon of April 7, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) said on the investor interaction platform that Lianhua Qingwen has been recommended by covid-19 pneumonia diagnosis and treatment program of more than 20 provinces (including autonomous regions and municipalities directly under the central government). At present, it is widely used in epidemic areas such as Shanghai and Jilin to help local epidemic prevention and control. In addition, the drug has been registered, approved and marketed in more than 20 countries such as Thailand, Canada and Russia. The company said it would continue to promote the overseas registration and sales of Lianhua Qingwen in the future.
Source: interactive easy
According to public information, in the first three quarters of 2021, Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) Lianhua Qingwen products achieved an operating revenue of 3.37 billion yuan, accounting for 41.6% of the company’s total operating revenue. The revenue of respiratory products represented by Lianhua Qingwen increased from 1.703 billion yuan in 2019 to 4.256 billion yuan in 2020, a year-on-year increase of 149.89%.
It is worth mentioning that according to the Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) 2020 interim report, an investor named “Ma Yun” held 4.5803 million shares and entered the list of the company’s top ten circulating shareholders, which has been continuously increased since then. In the third quarter of 2021, Ma Yun held 7.3731 million Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) shares, ranking the seventh largest circulating shareholder of the company. The reporter of China Securities Journal noted that some investors inquired about the matter on the interactive exchange. The company responded on April 7 that it “didn’t know the relevant details of Mr. Alibaba Ma Yun”.
Recently, there have been frequent positive news in the traditional Chinese medicine sector. On March 31, the WHO website released the report of the WHO expert evaluation meeting on the treatment of covid-19 pneumonia with traditional Chinese medicine, which clearly affirmed the safety and effectiveness of traditional Chinese medicine in the treatment of covid-19 pneumonia, and encouraged WHO Member States to consider China’s integrated traditional Chinese and Western medicine model (Integrated Medicine model).
At the press conference on epidemic prevention and control in Shanghai held on April 5, Fang min, President of Shuguang Hospital Affiliated to Shanghai University of traditional Chinese medicine and head of the epidemic prevention and control base of traditional Chinese medicine, said that traditional Chinese medicine had played a positive role in covid-19 epidemic prevention and control. For those with positive infection in Shanghai, the utilization rate of traditional Chinese medicine remained stable at more than 98%, and traditional Chinese medicine anti epidemic prescriptions were welcomed by patients.
Recently, many places have also strengthened the use of traditional Chinese medicine in response to covid-19 epidemic. Shanghai, Hebei and other places have successively received Lianhua Qingwen and other epidemic prevention materials.
Source: Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) WeChat official account
Sinolink Securities Co.Ltd(600109) said that from 2022 to 2023, it is expected that the large volume of overseas market, the growth of patients with mild and moderate diseases in China during the observation period, and the potential self-care demand of residents will become the new growth points of Shijiazhuang Yiling Pharmaceutical Co.Ltd(002603) Lianhua Qingwen. The sales of Lianhua Qingwen from 2022 to 2023 will reach 4.3 billion yuan and 4.7 billion yuan.
